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Abstract
Background: Earlier studies have reported the production of histamine in colorectal cancers (CRCs). The effect of
histamine is largely determined locally by the histamine receptor expression pattern. Recent evidence suggests that
the expression level of histamine receptor H4 (HRH4) is abnormal in colorectal cancer tissues. However, the role of
HRH4 in CRC progression and its clinical relevance is not well understood. The aim of this study is to evaluate the
clinical and molecular phenotypes of colorectal tumors with abnormal HRH4 expression.
Methods: Immunoblotting, real-time PCR, immunofluorescence and immunohistochemistry assays were adopted
to examine HRH4 expression in case-matched CRC samples (n = 107) and adjacent normal tissues (ANTs). To assess
the functions of HRH4 in CRC cells, we established stable HRH4-transfected colorectal cells and examined cell
proliferation, colony formation, cell cycle and apoptosis in these cells.
Results: The protein levels of HRH4 were reduced in most of the human CRC samples regardless of grade or
Dukes classification. mRNA levels of HRH4 were also reduced in both early-stage and advanced CRC samples. In
vitro studies showed that HRH4 over-expression caused growth arrest and induced expression of cell cycle proteins
in CRC cells upon exposure to histamine through a cAMP -dependent pathway. Furthermore, HRH4 stimulation
promoted the 5-Fu-induced cell apoptosis in HRH4-positive colorectal cells.
Conclusion: The results from the current study supported previous findings of HRH4 abnormalities in CRCs.
Expression levels of HRH4 could influence the histamine-mediated growth regulation in CRC cells. These findings
suggested a potential role of abnormal HRH4 expression in the progression of CRCs and provided some new clues
for the application of HRH4-specific agonist or antagonist in the molecular therapy of CRCs.
Background
Colorectal cancer is the uncontrolled growth of malig-
nant cells in the colon or rectum. It is currently the
third most common cancer in the Chinese population,
responsible for about 130,000 deaths per year. The
growth of CRC cells is influenced by various factors
such as insulin-like growth factors (IGF) [1], endothelial
growth factor [2,3] and epidermal growth factor receptor
[4-6].
Histamine and histamine receptors, previously identi-
fied as critical molecules during inflammation, are also
involved in the control of CRC growth [7-10]. Hista-
mine is a ubiquitous chemical messenger that exhibits
numerous functions and may act as ans [7,11,12]. His-
tamine levels in cells and tissues are regulated by the
activity of histidine decarboxylase (HDC), the only
enzyme responsible for the generation of histamine
from L-histidine. Therefore, HDC can serve as a speci-
fic marker for the biosynthesis of histamine. It has
been shown that the levels of HDC mRNA protein and
its enzymatic activity are significantly increased in both
experimental and human tumors, including colorectal
carcinoma [10,13-15].
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any medium, provided the original work is properly cited.The biological function of histamine is mediated
through at least four pharmacologically distinct recep-
tors, histamine receptor H1-4( H R H 1 - 4 ) ,w h i c ha r ea l l
members of the G-protein-coupled receptor (GPCR)
family. HRH1 and H2 have previously been indicated to
be correlated with histamine-mediated tumor growth
[8,16]. Recently, accumulated evidence indicates that
histamine receptor H4 (HRH4) also plays a role in cell
proliferation, both in normal and malignant cells,
including hematopoietic progenitor cells [17], breast
cancer cells [18] and pancreatic carcinoma cells [19].
H4 receptor is positively expressed along the human
gastrointestinal tract [20]. Nonetheless, whether HRH4
plays a role in the epithelium of alimental canal or col-
orectal tumor progression remains unclear. Boer et al.
reported the down-regulation of HRH4 expression in
human colorectal tumors, which indicated the distur-
bance of local tumor growth regulation by histamine
[21]. However, an earlier study showed a different result
when the H4R expression in CRC tissue and the corre-
sponding normal colon mucosa is compared [22].
Therefore, more data from clinical samples are required
to establish the role of H4R expression in CRC
carcinogenesis.
In the current study, a relatively high number (n =
107) of CRC samples together with matched adjacent
normal tissues (ANTs) were collected and used for the
examination of H4R expression. We found that both the
protein and mRNA levels of HRH4 were decreased in
CRC tissues compared with matched ANTs. In vitro stu-
dies using colorectal cell line showed that alteration of
HRH4 expression on colorectal cancer cells affected his-
tamine-mediated cell growth control, implicating the
cAMP/PKA pathway in this progress. These findings
suggested a potential role of HRH4 abnormalities in
CRC progression.
Methods
Patients and Tissue Collection
CRC samples were obtained from 107 surgical patients
from the Department of Gastroenterology, Shenzhen
Hospital, Peking University. Adjacent normal mucosa
samples located at least 2 cm from the macroscopically
unaffected margins of the tumor (polyp or carcinoma)
were defined as normal controls. All tumors that were
adenocarcinomas and mucinous carcinomas (when
>50% of the tumor volume was composed of mucin)
were excluded. Adenocarcinomas were staged according
to the Dukes classification system: Dukes A (T1-T2,N 0 ,
and M0;n=2 1 ) ,D u k e sB( T 3-T4,N 0 ,a n dM 0; n = 36),
Dukes C (any T, N1-2,M 0; n = 39) and Dukes D (any T
and any N and M1; n = 11). Tissue samples for Western
blot analysis were placed immediately in the lysis buffer
and frozen at -20°C. All patients were informed about
the aims of specimen collection and given signed written
consent in accordance with the ethical guidelines of
Peking University. The study was approved by the ethi-
cal committee of Peking University Shenzhen Hospital.
Cells and culture conditions
The human colorectal cancer cell lines, Colo-320 and
Lovo, were obtained from the Department of Biochemis-
try, Hong Kong University of Science and Technology.
The cell lines, whose characteristics are described in
detail elsewhere [23,24], were propagated in Dulbecco’s
modified Eagle’s medium (DMEM, Gibco), supplemen-
ted with 10% fetal bovine serum (PAA) and 1% penicil-
lin/streptomycin (Life Technologies, Inc.).
Plasmids and transfection
The cloned HRH4 cDNA fragment was inserted into
pcDNA3.1 expression vector to construct the HRH4
expression vector pcDNA3-HRH4. To produce stable
transfectants, pcDNA-HRH4 and mock plasmids were
stably transfected into the Lovo line using Lipofectamine
2000 reagent (LF2000, Invitrogen, Carlsbad, CA) accord-
ing to the manufacturer’s recommendations. Selection
was performed via the addition of 1mg/ml G418. Posi-
tive (pcDNA3-HRH4) and negative (empty vector)
clones were selected and transfectants with moderate
expression levels of HRH4 were used for the experi-
ments described herein. The transfectants from the
backbone vector and pcDNA3-HRH4 were designated
as mock-Lovo and H4R-Lovo, respectively.
Western Blotting
Cells were washed with PBS and lysed in a buffer con-
taining 50 mM Tris-HCl (pH 6.8), 1% SDS, 10% gly-
cerol, phosphatase inhibitors (100mM Na3VO4,1 0m M
NaF), and protease inhibitor (1mM PMSF). Equal
amounts of protein were loaded onto a SDS-PAGE and
transferred to PVDF membrane. After blocking with 5%
non-fat milk in TBS-T (containing 0.1% Tween-20), the
membranes were incubated with specific primary anti-
bodies, followed by HRP-conjugated secondary antibo-
dies. Proteins were visualized by fluorography using an
enhanced chemiluminescence system.
RT-PCR and Real-time quantitative PCR
Total RNA was isolated using the Trizol system accord-
ing to the manufacturer’sg u i d e l i n e s .O l i g o ( d T )1 8p r i -
mer and M-MLV reverse transcriptase were used for
first strand synthesis. The cDNA was then used as tem-
plate for real-time PCR and RT-PCR with gene specific
primers. Real-time PCR was performed with Real-time
PCR Master Mix containing SYBR GREEN I and hot-
start Taq DNApolymerase. GAPDH was amplified as
control. The primers for HRH4 and GAPDH are: HRH4
Fang et al. BMC Cancer 2011, 11:195
http://www.biomedcentral.com/1471-2407/11/195
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(antisense): ‘-AGG CAG AGG TTG CAG TGA-’,P C R
product length was 123 bp; hGAPDH(Sense): 5’-CAG
CCT CAA GAT CAT CAG CA-3’;h G A P D H ( a n t i -
sense): 5’-TGT GGT CAT GAG TCC TTC CA-3’ PCR
product length was 105 bp. Real-time detection of the
emission intensity of SYBR GREEN bound to double-
stranded DNAs was performed using the Icycler Instru-
ment (Bio-rad). At the end point of PCR cycles, melt
curves were made to check product purity. The level of
ITGA5 mRNA was expressed as a ratio relative to the
GAPDH mRNA in each sample.
To determine the amplification efficiency of HRH4
cDNA in this study, a standard curve was prepared
using 2 μl of sample cDNA solutions, in which serially
diluted samples (original, 2-, 4-, 8-, 16-diluted) were
included. The slopes of Ct and dCt ((target gene)-(refer-
ence gene)) and R
2 values of each sample were calcu-
lated by the BioRad Chromo4 real-time PCR system and
Microsoft Excel 2007 for Windows. Relative quantifica-
tion of HRH4 was performed with the 2
-ddCt method
[25]. The results were obtained from 3 reactions in each
sample and analyzed by the Boxplot software.
Immunofluorescence Staining
We selected a number of CRC samples with significantly
attenuated HRH4 expression (according to results from
Western blot, n = 15) to make paraffin-embedded tissue
sections (4 μm thick). After fixation by 2% paraformal-
dehyde for 15 min, the coverslips were blocked by rabbit
serum (Sigma) for 1 h, followed by incubation with anti-
HRH4- antibody (1:50, CHEMICON, US) for 1 h. After
washing with 0.01% saponin in PBS 3 times for 15 min
each, the coverslips were incubated with secondary anti-
body conjugated with CY3 (Jackson Immuno Research,
US) for another hour. The slips were then washed and
DAPI solution was used for nuclear stain. The coverslips
were further washed with 0.01% saponin in PBS, 3
times, 15 min each, and PBS twice, 10 min each. Then
the coverslips were mounted in an appropriate anti-fade
mounting medium. Fluorescence was observed using an
Olympus biological fluorescence microscope (IX2-
ILL100).
Immunohistochemistry
Immunohistochemical analysis was performed on 4%
formaldehyde-fixed and paraffin-embedded sections of
selected samples (n = 20). The paraffin sections were
deparaffinized in xylene and hydrated with ethanol. The
slides were treated with 3% H2O2 in methanol for 10
min and blocked with serum blocking solution for 10
min to reduce nonspecific background. The affinity-pur-
ified anti-HRH4 rabbit polyclonal antibody (CHEMI-
CON, US, 1:50) was applied to the slides and incubated
at room temperature for 1 h. The slides were then incu-
bated with biotinylated goat anti-rabbit secondary anti-
body (kit supply) at room temperature for 10 min
followed by streptavidin peroxidase conjugate for 10
min. 3,3’-Diaminobenzidine (DAB) solution was added
as a peroxidase substrate and incubated for 15 min. Cell
nuclei were counterstained by hematoxylin to give a
blue background contrast to the red color of the positive
reaction. The sections were cover-slipped and viewed
under fluorescence microscope (Nikon ECLIPSE 80i,
JPN).
Cell Proliferation and cloning-forming (clone-forming?)
ability
Cell proliferation was measured by WST-1 assay. Mock-
Lovo and H4R-Lovo cells were plated in 96-well culture
plates (1×10
4 per well) and treated with or without clo-
zapine/histamine. WST-1 (Roche) assay measuring the
activity of mitochondrial dehydrogenases was performed
following the manufacturer’s instruction at 0-, 1-, 2-, 3-,
4-, 5- day time points.
To determine long-term effects, cologenic (clono-
genic?) assay was used to elucidate the possible differ-
ences in the long-term effects of altered HRH4
expression on human colorectal cancer cells. Mock-
Lovo and H4R-Lovo cells were trypsinized and counted
using a hemocytometer. Cells (2×10
4) were plated in the
6-well dishes and supplemented with histamine or clo-
zapine 24 h later. Two weeks after the onset of drug
selection, the cells were fixed and stained with crystal
violet (0.1% crystal violet in 20% methanol). A cluster of
a minimum of 50 cells is considered a colon (clone? col-
ony). (I am not familiar with cancer so please check)
Flow cytometric analysis of cell cycle
For cell-cycle assay, cells were trypsinized with 2mM
EDTA in PBS and rinsed twice with ice-cold PBS solu-
tion, then fixed by adding them drop-wise into 75% ice-
cold ethanol while vortexing, followed by incubation in
ice for 60 min. The fixed cells were washed with ice-
cold PBS and incubated at 37°C for 30 min in 0.5 ml
PBS solution containing 20 μg/ml RNaseA, 0.2% Triton
X-100, 0.2mM EDTA and 20 μg/ml of propidium
iodide. The percentage of cells in G0/G1, S, and G2/M
phases was determined using the EPICS-XL flow cyt-
ometer (Beckman-Coulter, USA) and the Multicycler
program.
Analysis of cell death
Cells were seeded in a growth medium at 1×10
5 cells/
35-mm dish, allowed to attach overnight, and treated
with 10mM 5-Fu for 36 h. Cells were harvested with
trypsin, washed once, and resuspended in Dulbecco’s
modified Eagle’s medium. To detect annexin V, cells
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for 20 min at 37°C and then washed to remove unbound
annexin. Propidium iodide was added, and the cells were
incubated for an additional 15 min. The labeled cells
were analyzed by flow cytometry. Cells that showed
EGFP staining were designated as apoptotic, whereas
the double stained cells were designated as post-
apoptotic.
TUNEL labeling was also used to examine cell death
in cultures exposed to 5-Fu. Cells on coverslips were
fixed in 4% paraformaldehyde, pH 7.4, for 30 min and
permeabilized for 30 min in 0.1% Triton X-100/PBS at
room temperature, and apoptotic nuclei were detected
using a TUNEL-labeling reaction according to the man-
ufacturer’s instructions (Roche Biochemicals), as
described previously[26].
Statistical analysis
Statistical analysis was performed with the SPSS Soft-
ware, version 12. Data were analyzed by the chi-square
test or Fisher exact test. P values less than 0.05 were
considered statistically significant. Results of HRH4
mRNA expression for normal and tumor tissue samples
were compared using two-way repeated measurement
ANOVA.
Results
Impaired HRH4 expression in CRCs in a Chinese
population
We first examined the H4R protein levels in the case-
matched CRC samples and adjacent normal tissues. As
shown in Figure 1A &1B, attenuated expression levels of
HRH4 were detected in most CRC samples compared to
matched ANTs, regardless of the Dukes classification.
Based on these results, we performed real-time RT-PCR,
immunocytochemistry, and immunohistochemical analy-
sis of the matched adjacent normal mucosa and adeno-
carcinoma samples. It was found that HRH4 mRNA
levels were also significantly reduced in the CRCs (Fig-
ure 1C, p < 0.001), and there was a statistical difference
between the group of early-stage CRCs and advanced
CRCs (p < 0.05). Some of the results were confirmed by
RT-PCR, which were shown in Additional file 1 Figure
1. Figure 1D &1E showed the representative immunocy-
tochemistry and immunohistochemical analysis of
HRH4 expression in selected CRC samples. The results
obtained were in accordance with the data from the
immunoblotting.
Restoration of HRH4 in colorectal cancer cell line resulted
in impaired proliferation upon exposure to HRH4 agonist
To investigate the role of impaired HRH4 expression in
colorectal cancer, in vitro experiments using CRC cell
lines were performed. We first assessed the expression
of HRH4 in 12 colorectal cancer cell lines (Additional
file 1 Figure S2). The cell line with relatively lower
expression of HRH4, Lovo line, was stably transfected
with HRH4 expression construct and then named as
H4R-Lovo. Lovo cells transfected with the backbone
vector were named as mock-Lovo (Figure 2A).
HRH4 has been implicated in cell growth control in
various types of cells [17-19]. Here we evaluated
whether manipulation of the activation level of HRH4
regulates cell cycle status of the stable cell lines. We
used histamine, the natural ligand of HRH4, and cloza-
pine, one of the most specific agonist of HRH4, to acti-
vate HRH4. Although clozapine was capable of
activating both HRH3 and H4, it could be used as
HRH4-specific agonist here because there was no appre-
ciable H3R expression in Mock-Lovo or H4R-Lovo cells
(Figure 2A). It was found that both histamine and cloza-
pine inhibited proliferation of H4R-Lovo cells at an opti-
mal dose of 10
-5 M, as illustrated by the accumulation
of cells at stage G0/G1 and a decrease at stage G2/S,
when either histamine or clozapine treatment has little
influence on Mock-Lovo cells (Figure 2B) (This sentence
is a little hard to understand. Need to rephrase). More-
over, pre-treatment with the selective HRH4 antagonist
JNJ7777120 before exposure to histamine or clozapine
prevented the cell cycle arrest, providing additional evi-
dence that activation of HRH4 leads to cell cycle arrest.
To determine whether the alteration of HRH4 expres-
sion in Lovo cells affects long-term tumor growth, we
evaluated the growth rate of H4R-Lovo and mock-Lovo
cells that were incubated with the medium containing
histamine (10
-5M) or clozapine (10
-5M). As shown in
Figure 2C, cells transfected with the HRH4 gene gener-
ated a lower number of colonies than those transfected
with the backbone vector after HRH4 agonist treatment.
Moreover, we analyzed the growth potential of H4R-
Lovo cells by WST-1 assay at different times after plat-
ing. It was found that H4R-Lovo cells grew at a signifi-
cantly slower rate when incubated with a medium
containing histamine or clozapine, while growth of
Mock-Lovo cells was not influenced by the HRH4 ago-
nist (Figure 2D).
We also used another specific HRH4 agonist, cloben-
propit (CB), to investigate the role of HRH4 in colon
cancer proliferation, and similar results were obtained
(A part of results were shown in Additional file 1 Figure
S3).
Effect of HRH4 activation on cell-cycle regulatory
molecules
The clozapine-induced G1 arrest was further confirmed
by examining the cellular levels of the G1 cell-cycle con-
trol proteins cyclin D1 and Cdk2 in H4R-Lovo cells.
Western immunoblotting analysis confirmed that
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Page 4 of 11Figure 1 Attenuated HRH4 expression in CRCs. (A) Representative blots of HRH4 expression in normal mucosa and colorectal tumor tissues.
Sample 1, 2: Dukes A; sample3, 4: Dukes B; sample5, 6: Dukes C; sample7, 8: Dukes D. GAPDH was used as a stable endogenous control. (B)
Analysis of HRH4 protein level in CRC samples. Quantitative image of blot were calculated using TotalLab TL100 software, and quantities of
GAPDH were used to normalize the HRH4 expression data. The expression level of HRH4 in each sample was calculated as the ratio between
CRC tissues and matched adjacent normal tissue. Each data was obtained from two independent results of immunoblottings. (C) Real-time PCR
assay was carried out as described under Materials and Methods section, boxplots of relative HRH4 mRNA(HRH4/GAPDH) measured with real-
time PCR analysis showing median; box: 25th -75th percentile; bars: largest and smallest values within 1.5 box lengths; little circles: outliers. The
results were obtained from 3 reactions in each sample. (D) Representative immunofluorescent microscope analysis of paired samples of CRC
tissue and adjacent normal tissue using anti human HRH4 monoclonal antibody (red). Nuclei were stain with DAPI (blue). Sample1: rectum tissue;
sample2: colon tissue, white arrow points to the positive control of HRH4 expression on blood vessel epithelium. (E) Representative
immunohistochemical staining of paired samples of CRC tissue and adjacent normal tissue using anti human HRH4 monoclonal antibody.
Sample1: rectum; sample2: colon tissue. Black arrow points to the positive expression of HRH4 expression on enterocytes.
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Page 5 of 11Figure 2 HRH4 activation induced growth arrest in colorectal carcinoma cell lines. (A) Total cell lysates of wild type Lovo, Mock-Lovo and
H4R-Lovo cells were examined by Western blotting. (B) Mock-Lovo and H4R-Lovo cells were treated with 10
-5M histamine, clozapine or
clozapine accompanied by HRH4 antagonist pretreatment, and cell-cycle distributions were determined by propidium iodide flow cytometry
analysis. *p < 0.05 and **p < 0.01 vs. Control, H4R-Lovo cells without any treatment. (C) Colony-formation assay. 5×10
3 Mock-Lovo and H4R-Lovo
cells were treated as in Fig.2B and maintained in G418 for 14 days, and the colonies were stained with Giemsa. The bar graph shows the
absolute colony (≥50 cells) number ± s.e. in duplicate experiments. (D) H4R-Lovo cells were treated as in Fig.2B, WST-1 (Roche) assay measuring
the activity of mitochondrial dehydrogenases was performed following the manufacturer’s instruction at 0-, 1-, 2-, 3-, 4-, 5- day time points. Error
bars represent standard deviation of the mean.
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Page 6 of 11treatment with 10
-5M clozapine down-regulated the
levels of cyclin D1 and Cdk2 proteins in H4R-Lovo cells
and the expression of p21
Cip1 and p27
Kip1 was substan-
tially up-regulated following 24h of clozapine stimula-
tion in a dose-dependent manner (Figure 3A). Based on
these findings, clozapine-mediated activation of HRH4
likely blocks cell-cycle progression from the G1 to S
phase. Relatively high concentrations of histamine (Fig-
ure 3B) mimics the effect of clozapine, suggesting the
potential role of increased histamine production and
reduced HRH4 expression in the tumor growth of
CRCs. Expression levels of cycle proteins in Mock-H4R
cells were not significantly influenced by clozapine or
histamine treatment, which further confirmed the role
of HRH4 in this process.
HRH4-mediated cell cycle control is mediated through
cAMP/PKA-dependent signaling
Activation of endogenously expressed H4 receptors in
e o s i n o p h i l sa n dm a s tc e l l sl e a d st oP T X - s e n s i t i v ec a l -
cium mobilization [27,28], via the activation of phospho-
lipase C. In human hematopoietic progenitor cells, T
cell or some cell lines recombinantly express H4 recep-
tor. However, HRH4 is coupled with pertussis toxin
(PTX)-sensitive Gai/o proteins, therefore inhibiting for-
skolin-induced cAMP and its-responsive elements
[17,29].
To elucidate the molecular basis for clozapine-induced
cell cycle arrest, we first examined whether cAMP/PKA
pathway was involved in HRH4-mediated cell cycle con-
trol. As shown in Figure 4A, activation of HRH4 sup-
pressed the level of intracellular cAMP in H4R-Lovo
cells. Clozapine inhibited cell cycle progression induced
by forskolin, a chemical commonly used to raise intra-
cellular cAMP levels (Figure 4B). Also, the cAMP inhibi-
tor Rp-8-Br-cAMPS mimicked the cell cycle arrest
induced by CZ in H4R-Lovo cells. Clozpine could not
block the effect of forskolin in Mock-Lovo cells, which
further indicated the specific role of HRH4 in the regu-
lation of cAMP pathway.
We also examined the expression levels of cell cycle
proteins in H4R-Lovo and Mock-Lovo cells treated with
cAMP inhibitors and agonists (Figure 4C). The results
were in accordance with those from flow cytometry ana-
lysis. Clozapine blocked forskolin-induced cell cycle pro-
gression in H4R-Lovo cells but not in Mock-Lovo cells.
This further supported the involvement of the cAMP/
PKA pathway in HRH4-mediated cell cycle regulation.
HRH4 activation could promote apoptosis induced by 5-
Fu treatment in colon cancer cells
HRH4 expression has been implicated in cell apoptosis
[30], and HRH4 agonist has been reported to induce
early-stage apoptosis in peripheral blood mononuclear
cells (PBMCs) [29]. Thus cell apoptosis may also be
involved in the H4R-mediated regulation of CRC
growth. In our preliminary work, the treatment of cloza-
pine or histamine could not directly induce evident
apoptosis in H4R-Lovo or Mock-Lovo cells. As an initial
approach to identify the influence of cell death by
HRH4 activity in CRCs, we treated H4R-Lovo cells with
5-fluorouracil (5-Fu, an anti-cancer drug proved to be
an inducer of both early and late stages of apoptosis in
colorectal cancer cells including Lovo line [31,32]) to
induce cell death. As shown in Figure 5A, incubation of
H4R-Lovo cells with clozapine and 5-Fu increased both
Figure 3 Expression of cell cycle proteins regulated by HRH4. (A) Mock-Lovo and H4R-Lovo were treated with clozapine at different doses
for 24h, and total cell lysates were examined by western blotting. One dish of H4R-lovo cells was pretreated with 10
-5M JNJ7777120 for 2 h. (B)
Mock-Lovo and H4R-Lovo were treated with 10
-5M histamine at for 5 h or 24 h, and total cell lysates were examined by western blotting.
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Page 7 of 11early and late stage of apoptosis, which was reversed by
HRH4 antagonist pre-treatment. We also used TUNEL
assay as another method to evaluate apoptosis. Staining
of H4R-Lovo cells in the presence of clozapine following
5-Fu treatment revealed augmented TUNEL-positive
cells (Figure 5B), which could be blocked by pre-
treatment with JNJ7777120. In addition, treatment with
5-Fu together with clozapine resulted in enhanced levels
of cleaved (89 kDa) PARP in H4R-Lovo cells (Figure
5C). These findings suggested a potential role of HRH4
in the apoptosis of CRC cells.
Discussion
The distribution of HRH1, HRH2 and HRH4 in human
intestinal tract has been described [20]. While the role
of H1R and H2R in different gastrointestinal tumor
models is well documented [11], the relevance of
HRH4 has yet to be clarified. Moreover, only limited
data on the level of HRH4 expression in colorectal
tumors have been reported. In this study, a relatively
large number of CRC samples with different Dukes
classifications were used for HRH4 analysis. Attenu-
ated H4R expression was observed in most CRC sam-
ples compared with case-matched ANTs, which
supported a previous report [21]. The mRNA levels of
HRH4 were also examined, which provided additional
evidence of transcriptionally repressed HRH4 gene in
CRCs. Interestingly, we found that expression levels of
HRH4 mRNA were lower in advanced CRCs (p <
0.05), which suggested that decrease of H4R expression
might mainly take place during CRC progression but
not during initiation. The immunohistochemical and
immunoflourescent approach further confirmed the
results from immunoblotting and provided additional
evidence for the positive expression of H4R on normal
enterocytes. These details may help us answer the
question of whether direct or indirect effects of hista-
mine, or both, mediated by HRH4, are responsible for
tumor progression in colorectal carcinoma.
To the best of our knowledge, no functional elucida-
tion of HRH4 expression in colorectal enterocytes has
been described. In the current study, results from the
in vitro experiments using CRC cell lines first indi-
cated the influence of HRH4 abnormalities on hista-
mine-mediated regulation of CRC growth. Another
CRC cell line with low endogenous HRH4 expression,
CACO-2, was also transfected with H4R expression
vector and used for cell cycle analysis. Similar results
were obtained (Additonal file1, Figure S4), which
further supported the role of HRH4 expression in
growth control of CRC cells.
HRH4 stimulation resulted in cell growth arrest and
increase of cyclin-dependent kinase inhibitor p21
Cip1
and p27
Kip1, cell cycle regulators with important func-
tions in cell cycle control and apoptosis of colorectal
cancer cells [33]. p21
Cip1 and p27
Kip1 play important
roles in mediating growth arrest and are considered to
function as brakes of the cell cycle [34]. Extensive stu-
dies have been published on the roles of p21
Cip1 and
p27
Kip1 in carcinogenesis of tumors, including colorectal
Figure 4 HRH4 activation regulates proliferation of colon
cancer cell through a cAMP-dependent pathway. (A) Mock-Lovo
and H4R-Lovo cells were exposed to 5mM clozapine for 10 min to
8 h. Intracellular cAMP levels were determined by cAMP Enzyme
Immunoassay Kit as introduced in Material and Methods. Values are
mean ± S.D. of two experiments performed in triplicate. (B) H4R-
Lovo and Mock-Lovo cells were treated with 10-5M forskolin,
forskolin together with clozapine or Rp-8-Br-cAMPS, and cell-cycle
distributions were determined by propidium iodide flow cytometry
analysis. *p < 0.05 vs. Control, cells without any treatment. (C) H4R-
Lovo and Mock cells were treated with clozapine, clozapine
together with FK or Rp-8-Br-cAMPS as in Fig.4B, and total cell lysates
were examined by Western blotting.
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Page 8 of 11Figure 5 HRH4 activation promotes 5-Fu-induced cell apoptosis in colon cancer cells. (A) H4R-Lovo cells were treated with 10mM 5-Fu, 5-
Fu together with clozapine(10
-5M) or 5-Fu (10mM) and clozapine with JNJ7777120(10
-5M) pretreatment, and cell apoptosis was assessed using
annexin V/PI staining and flow cytometry. *p < 0.05 vs. control, cells treated with 5-Fu (10mM) alone. (B) H4R-Lovo cells were treated as in
Fig.5A, and TUNEL-DAB staining was performed according to the guidance of the kit. *p < 0.05 vs. control, cells treated with 5-Fu alone. (C) H4R-
Lovo cells were treated as in Fig.5A, and total cell lysates were examined by Western blotting.
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Page 9 of 11cancer [33,35,36]. The increase in p21
Cip1 and p27
Kip1
could, by inhibiting cyclin D1/Cdk4 or Cdk6 kinase
activity, explain, at least partially, the increase of cells in
the G1 phase following clozapine treatment in our
study. Expression of p21 and p27 in H4R-Lovo cells
were also modulated by the use of a cAMP inhibitor.
This implies that a link exists between cAMP suppres-
sion and p21 and p27 induction by HRH4 activation.
However, the inhibitor of PKA had little effect on the
expression of p21 and p27 (data not shown here), indi-
cating that cAMP-mediated regulation of CKIs expres-
sion was independent of PKA activity. This was
consistent with a previous report [37].
HRH4 has been reported to influence apoptosis in ani-
mal models of sepsis through counteracting the anti-
apoptotic action of NF-kappaB [30], while the cAMP-
PKA pathway is involved in HRH4 activation-mediated
cell death in peripheral blood mononuclear cells
(PBMCs) [29]. In the current study, we showed that
HRH4 activation could promote the 5-Fu-mediated cell
apoptosis in colon cancer cells, which may provide new
clues for histamine receptor-targeted therapies of CRCs.
However, the molecular mechanisms involved in the
regulation of CRC cell apoptosis by HRH4 require
further investigation.
Overall, our results confirmed the down-regulation of
HRH4 expression in colorectal malignancies and sug-
gested a potential role of histamine-mediated growth
control in CRC cells. We also showed that expression
levels of HRH4 in CRC cells had an influence on cell
apoptosis induced by chemotherapeutic agent (s?). It
will be interesting to perform in vivo study aimed at
understanding the mechanisms of the HRH4 expression
levels using HRH4 KO mice in the future.
Conclusion
The results from the current study supported previous
findings of HRH4 abnormalities in CRCs. Expression
levels of HRH4 could influence the histamine-mediated
growth regulation in CRC cells. These findings sug-
gested a potential role of abnormal HRH4 expression in
the progression of CRCs and provided some new clues
for the application of HRH4-specific agonist or antago-
nist in the molecular therapy of CRCs.
Additional material
Additional file 1: Supplementary figures. Figure S1: Comparison of
HRH4 mRNA expression between matched CRC tissues and adjacent
normal tissues using RT-PCR assay. GAPDH is used as the internal control.
Shown is representative example of multiple experiments; Figure S2:
mRNA levels of HRH4 in the colorectal cell lines were analyzed using RT-
PCR assay, and normalized with the amount of GAPDH. Shown is
representative example of multiple experiments. Figure S3: H4R-Lovo
cells were treated with 10
-5M HA, CB or CB together with JNJ7777120,
and cell-cycle distributions were determined by propidium iodide flow
cytometry analysis. *p < 0.05 vs. Control, H4R-Lovo cells without any
treatment. **p < 0.001 vs. Control, H4R-Lovo cells without any treatment.
Figure S4: HRH4 activation blocked cell cycle progression in CACO-2 cells.
CACO-2 cells were transiently transfected with HRH4 expression vector
for 24h. The wild-type CACO-2 cells and HRH4 transfectants were both
treated with 10
-5M histamine or clozapine for 24h. Cell-cycle distributions
were determined by propidium iodide flow cytometry analysis. *p < 0.05
vs. Control, cells without any treatment; **p < 0.001 vs. Control, cells
without any treatment.
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